BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RSR13: Phase II

Preliminary data from the first 30 patients with stage IIIA and IIIB NSCLC in ALTH's 47-patient open label Phase II trial showed a complete or partial response in 87 percent of patients...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >